language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
ELVELV

$330.33

+2.70
arrow_drop_up0.82%
Current Market·update13 Nov 2025 17:59
Day's Range
321.54-332.66
52-week Range
273.71-458.75

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-10-21
Next Earnings TimeBefore Market Open
Volume786.83K
Average Volume 30d1.93M

AI ELV Summary

Powered by LiveAI
💰
11.89
Valuation (P/E Ratio)
Reasonable valuation
📈
0.0319
Revenue Growth (YoY)
Consistent revenue growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Hold
65

Elevance Health (ELV) shows mixed signals. It has a solid financial foundation and participates in a growing healthcare market. However, recent performance shows a significant downturn, and valuation metrics like P/E are relatively high compared to its historical average and some industry peers. Technicals suggest a bearish short-term trend.

Positive

Thematic

75

Elevance Health operates in the expanding healthcare and health insurance sector, benefiting from demographic trends and increasing demand for managed care services. The company's diversified offerings, including pharmacy services and health-related capabilities, position it well within the resilient healthcare industry.

Neutral

Fundamental

60

Elevance Health demonstrates consistent revenue and earnings, with a solid balance sheet. However, the current P/E ratio is elevated relative to its past performance and future earnings estimates, and net margins have seen a slight decline. Dividend yield is modest.

Bearish

Technical

45

The stock has experienced a significant decline over the past 1 month (-24.85%) and 6 months (-31.22%), indicating strong downward momentum. Current technical indicators across multiple timeframes (1m, 5m, 15m, 1h, 2h, 4h, 1d) predominantly signal 'Sell' or 'Neutral', suggesting a prevailing bearish sentiment and a potential for further downside.

FactorScore
Healthcare & Health Insurance Demand85
Managed Care Services Growth80
Regulatory Landscape60
Digital Health & Innovation70
Economic Sensitivity70
FactorScore
Valuation65
Profitability55
Growth60
Balance Sheet Health70
Cash Flow75
Dividends60
FactorScore
Trend Analysis20
Momentum30
Volume Confirmation50
Support & Resistance40
Oscillators30

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Strong Earnings Beat

Most recent quarterly EPS estimate was $11.97, exceeding the estimate of $11.38 by 5.16%. This indicates strong current profitability.

Valuation chevron_right

Attractive P/E Ratio

The trailing P/E ratio is 11.89, which is generally considered attractive and suggests the stock may be undervalued relative to its earnings.

Show More 🔒
thumb_down

Bearish Points (7)

Performance chevron_right

Significant Recent Decline

The stock has experienced a -24.85% decline in the last month and -31.22% over the last 6 months, indicating significant recent downward price momentum.

Valuation chevron_right

High Forward P/E

The projected P/E ratio for Q2 2025 is 50.2, which is significantly higher than the trailing P/E, suggesting future earnings expectations may be very optimistic or that the stock is expensive on a forward-looking basis.

Show More 🔒

Calendar

September 2025

10

Ex-Dividend Date

September 2025

25

Next Dividend Date

October 2025

16

Next Earnings Date

EPS Est.
Revenue Est.

H: $8.97

A: $5.89

L: $4.47

H: 50.20B

A: 49.18B

L: 48.14B

Profile

Employees (FY)104K
ISINUS0367521038
FIGI-

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Seasonals

2025
2024
2023
2022
2021

Price Target

392.28 USD

The 39 analysts offering 1 year price forecasts for ELV have a max estimate of 556.33 and a min estimate of 310.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
225M (99.77%)
Closely held shares
520K (0.23%)
225M
Free Float shares
225M (99.77%)
Closely held shares
520K (0.23%)

Capital Structure

Market cap
63.15B
Debt
31.23B
Minority interest
0.00
Cash & equivalents
8.29B
Enterprise value
86.09B

Valuation - Summary

Market Cap
63.1B
Net income
5.36B(8.49%)
Revenue
189B(299.71%)
63.1B
Market Cap
63.1B
Net income
5.36B(8.49%)
Revenue
189B(299.71%)
Price to earning ratio (P/E)11.80x
Price to sales ratio (P/S)0.30x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
176.81B
COGS
176.81B
Gross Profit
0.00
OpEx
0.00
Operating Income
0.00
Other & Taxes
-5.98B
Net Income
5.98B

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒